.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 9,433,606

« Back to Dashboard

Details for Patent: 9,433,606

Title:Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoi- soindoline-1,3-dione, compositions thereof, and uses thereof
Abstract: Solid forms comprising (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoi- soindoline-1,3-dione, compositions comprising the solid forms, methods of making the solid forms and methods of their use are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-.alpha. or the inhibition of PDE4.
Inventor(s): Muller; George W. (Rancho Santa Fe, CA), Schafer; Peter H. (Belle Mead, NJ), Man; Hon-Wah (Princeton, NJ), Ge; Chuansheng (Belle Mead, NJ), Xu; Jean (Warren, NJ)
Assignee: Celgene Corporation (Summit, NJ)
Filing Date:Mar 26, 2015
Application Number:14/670,336
Claims:1. A method of treating sarcoidosis, the method comprising administering to a patient having sarcoidosis a therapeutically effective amount of a Form B crystal form of the compound of Formula (I): ##STR00002## which is enantiomerically pure, and which has an X-ray powder diffraction pattern comprising peaks at about 10.1, 13.5, 20.7, and 26.9 degrees 2.theta..

2. The method of claim 1, wherein the crystal form has an X-ray powder diffraction pattern further comprising peaks at about 12.4, 15.7, 18.1, and 24.7 degrees 2.theta..

3. The method of claim 2, wherein the crystal form has an X-ray powder diffraction pattern further comprising peaks at about 16.3, 22.5, 26.2, and 29.1 degrees 2.theta..

4. The method of claim 1, wherein the crystal form has an X-ray powder diffraction pattern matching the pattern depicted in FIG. 5.

5. The method of claim 1, wherein the crystal form has a differential scanning calorimetry plot comprising an endothermic event with an onset temperature of about 154.degree. C.

6. The method of claim 1, wherein the crystal form has a differential scanning calorimetry plot matching the plot depicted in FIG. 6.

7. The method of claim 1, wherein the crystal form has a thermal gravimetric analysis plot comprising a mass loss of less than about 1% when heated from about 25.degree. C. to about 140.degree. C.

8. The method of claim 7, wherein the mass loss is about 0.25%.

9. The method of claim 1, wherein the crystal form has a thermal gravimetric analysis plot matching the plot depicted in FIG. 7.

10. The method of claim 1, wherein the crystal form exhibits a mass increase of less than about 1% when subjected to an increase in relative humidity from about 0% to about 95% relative humidity.

11. The method of claim 10, wherein the mass increase is about 0.6%.

12. The method of claim 1, wherein the crystal form has a moisture sorption isotherm plot matching the plot depicted in FIG. 8.

13. The method of claim 1, wherein the crystal form is stable upon exposure to about 40.degree. C. and about 75% relative humidity for about 4 weeks.

14. The method of claim 1, wherein the sarcoidosis is pulmonary sarcoidosis.

15. The method of claim 1, wherein the sarcoidosis is cutaneous sarcoidosis.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc